Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion

Results of the pan american collaborative retina study group at 24 months

Lihteh Wu, J Fernando Arevalo, Maria H. Berrocal, Mauricio Maia, José A. Roca, Virgilio Morales-Cantón, Arturo A. Alezzandrini, Manuel J. Díaz-Llopis

Research output: Contribution to journalArticle

Abstract

Purpose: The purpose of this study was to compare the injection burden, central macular thickness (CMT), and change in best-corrected visual acuity after injecting 1.25 mg or 2.5 mg bevacizumab as needed in patients with primary macular edema secondary to central retinal vein occlusion. Methods: This is an interventional, retrospective, comparative multicenter study of 86 eyes with macular edema secondary to central retinal vein occlusion that were treated primarily with intravitreal bevacizumab (44 eyes, 1.25 mg; 42 eyes, 2.5 mg). The main outcome measures were the CMT and the change of best-corrected visual acuity at 24 months. Results: All patients completed at least 24 months of follow-up. The mean number of injections per eye were 7.2 for the 1.25-mg dose group and 8.1 for the 2.5-mg dose group (P = 0.4492). At 24 months, in the 1.25-mg dose group, the logarithm of the minimal angle of resolution best-corrected visual acuity improved from baseline 0.35 ± 0.57 units (P <0.0001) versus 0.27 ± 0.68 units for the 2.5-mg dose group (P <0.0001). These differences were not statistically significant between both dose groups. In the 1.25-mg dose group, 25 (56.8%) eyes gained ≥3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity and 6 (13.6%) lost ≥3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. In the 2.5-mg dose group, 24 (57.1 %) eyes improved ≥3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity and 7 (16.7%) lost ≥3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. The CMT in the 1.25-mg dose group improved from 635 ± 324 μm to 264 ± 160 μm (P <0.0001) versus 528 ± μm to 293 ± 137 μm in the 2.5-mg dose group (P <0.0001). There was no statistically significant difference between both dose groups with regard to the CMT reduction. Conclusion: Intravitreal bevacizumab at doses up to 2.5 mg seems to be effective in improving visual acuity and reducing CMT in macular edema secondary to central retinal vein occlusion. There were no statistically significant differences between the two dose groups with regard to the number of injections, CMT, and change in visual acuity.

Original languageEnglish (US)
Pages (from-to)1002-1011
Number of pages10
JournalRetina
Volume30
Issue number7
DOIs
StatePublished - Jul 2010

Fingerprint

Retinal Vein
Retinal Vein Occlusion
Macular Edema
Visual Acuity
Retina
Diabetic Retinopathy
Therapeutics
Injections
Bevacizumab
Multicenter Studies
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion : Results of the pan american collaborative retina study group at 24 months. / Wu, Lihteh; Arevalo, J Fernando; Berrocal, Maria H.; Maia, Mauricio; Roca, José A.; Morales-Cantón, Virgilio; Alezzandrini, Arturo A.; Díaz-Llopis, Manuel J.

In: Retina, Vol. 30, No. 7, 07.2010, p. 1002-1011.

Research output: Contribution to journalArticle

Wu, Lihteh ; Arevalo, J Fernando ; Berrocal, Maria H. ; Maia, Mauricio ; Roca, José A. ; Morales-Cantón, Virgilio ; Alezzandrini, Arturo A. ; Díaz-Llopis, Manuel J. / Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion : Results of the pan american collaborative retina study group at 24 months. In: Retina. 2010 ; Vol. 30, No. 7. pp. 1002-1011.
@article{5c29592d2ec14b23825c4f33b481ce70,
title = "Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: Results of the pan american collaborative retina study group at 24 months",
abstract = "Purpose: The purpose of this study was to compare the injection burden, central macular thickness (CMT), and change in best-corrected visual acuity after injecting 1.25 mg or 2.5 mg bevacizumab as needed in patients with primary macular edema secondary to central retinal vein occlusion. Methods: This is an interventional, retrospective, comparative multicenter study of 86 eyes with macular edema secondary to central retinal vein occlusion that were treated primarily with intravitreal bevacizumab (44 eyes, 1.25 mg; 42 eyes, 2.5 mg). The main outcome measures were the CMT and the change of best-corrected visual acuity at 24 months. Results: All patients completed at least 24 months of follow-up. The mean number of injections per eye were 7.2 for the 1.25-mg dose group and 8.1 for the 2.5-mg dose group (P = 0.4492). At 24 months, in the 1.25-mg dose group, the logarithm of the minimal angle of resolution best-corrected visual acuity improved from baseline 0.35 ± 0.57 units (P <0.0001) versus 0.27 ± 0.68 units for the 2.5-mg dose group (P <0.0001). These differences were not statistically significant between both dose groups. In the 1.25-mg dose group, 25 (56.8{\%}) eyes gained ≥3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity and 6 (13.6{\%}) lost ≥3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. In the 2.5-mg dose group, 24 (57.1 {\%}) eyes improved ≥3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity and 7 (16.7{\%}) lost ≥3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. The CMT in the 1.25-mg dose group improved from 635 ± 324 μm to 264 ± 160 μm (P <0.0001) versus 528 ± μm to 293 ± 137 μm in the 2.5-mg dose group (P <0.0001). There was no statistically significant difference between both dose groups with regard to the CMT reduction. Conclusion: Intravitreal bevacizumab at doses up to 2.5 mg seems to be effective in improving visual acuity and reducing CMT in macular edema secondary to central retinal vein occlusion. There were no statistically significant differences between the two dose groups with regard to the number of injections, CMT, and change in visual acuity.",
author = "Lihteh Wu and Arevalo, {J Fernando} and Berrocal, {Maria H.} and Mauricio Maia and Roca, {Jos{\'e} A.} and Virgilio Morales-Cant{\'o}n and Alezzandrini, {Arturo A.} and D{\'i}az-Llopis, {Manuel J.}",
year = "2010",
month = "7",
doi = "10.1097/IAE.0b013e3181cea68d",
language = "English (US)",
volume = "30",
pages = "1002--1011",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion

T2 - Results of the pan american collaborative retina study group at 24 months

AU - Wu, Lihteh

AU - Arevalo, J Fernando

AU - Berrocal, Maria H.

AU - Maia, Mauricio

AU - Roca, José A.

AU - Morales-Cantón, Virgilio

AU - Alezzandrini, Arturo A.

AU - Díaz-Llopis, Manuel J.

PY - 2010/7

Y1 - 2010/7

N2 - Purpose: The purpose of this study was to compare the injection burden, central macular thickness (CMT), and change in best-corrected visual acuity after injecting 1.25 mg or 2.5 mg bevacizumab as needed in patients with primary macular edema secondary to central retinal vein occlusion. Methods: This is an interventional, retrospective, comparative multicenter study of 86 eyes with macular edema secondary to central retinal vein occlusion that were treated primarily with intravitreal bevacizumab (44 eyes, 1.25 mg; 42 eyes, 2.5 mg). The main outcome measures were the CMT and the change of best-corrected visual acuity at 24 months. Results: All patients completed at least 24 months of follow-up. The mean number of injections per eye were 7.2 for the 1.25-mg dose group and 8.1 for the 2.5-mg dose group (P = 0.4492). At 24 months, in the 1.25-mg dose group, the logarithm of the minimal angle of resolution best-corrected visual acuity improved from baseline 0.35 ± 0.57 units (P <0.0001) versus 0.27 ± 0.68 units for the 2.5-mg dose group (P <0.0001). These differences were not statistically significant between both dose groups. In the 1.25-mg dose group, 25 (56.8%) eyes gained ≥3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity and 6 (13.6%) lost ≥3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. In the 2.5-mg dose group, 24 (57.1 %) eyes improved ≥3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity and 7 (16.7%) lost ≥3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. The CMT in the 1.25-mg dose group improved from 635 ± 324 μm to 264 ± 160 μm (P <0.0001) versus 528 ± μm to 293 ± 137 μm in the 2.5-mg dose group (P <0.0001). There was no statistically significant difference between both dose groups with regard to the CMT reduction. Conclusion: Intravitreal bevacizumab at doses up to 2.5 mg seems to be effective in improving visual acuity and reducing CMT in macular edema secondary to central retinal vein occlusion. There were no statistically significant differences between the two dose groups with regard to the number of injections, CMT, and change in visual acuity.

AB - Purpose: The purpose of this study was to compare the injection burden, central macular thickness (CMT), and change in best-corrected visual acuity after injecting 1.25 mg or 2.5 mg bevacizumab as needed in patients with primary macular edema secondary to central retinal vein occlusion. Methods: This is an interventional, retrospective, comparative multicenter study of 86 eyes with macular edema secondary to central retinal vein occlusion that were treated primarily with intravitreal bevacizumab (44 eyes, 1.25 mg; 42 eyes, 2.5 mg). The main outcome measures were the CMT and the change of best-corrected visual acuity at 24 months. Results: All patients completed at least 24 months of follow-up. The mean number of injections per eye were 7.2 for the 1.25-mg dose group and 8.1 for the 2.5-mg dose group (P = 0.4492). At 24 months, in the 1.25-mg dose group, the logarithm of the minimal angle of resolution best-corrected visual acuity improved from baseline 0.35 ± 0.57 units (P <0.0001) versus 0.27 ± 0.68 units for the 2.5-mg dose group (P <0.0001). These differences were not statistically significant between both dose groups. In the 1.25-mg dose group, 25 (56.8%) eyes gained ≥3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity and 6 (13.6%) lost ≥3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. In the 2.5-mg dose group, 24 (57.1 %) eyes improved ≥3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity and 7 (16.7%) lost ≥3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. The CMT in the 1.25-mg dose group improved from 635 ± 324 μm to 264 ± 160 μm (P <0.0001) versus 528 ± μm to 293 ± 137 μm in the 2.5-mg dose group (P <0.0001). There was no statistically significant difference between both dose groups with regard to the CMT reduction. Conclusion: Intravitreal bevacizumab at doses up to 2.5 mg seems to be effective in improving visual acuity and reducing CMT in macular edema secondary to central retinal vein occlusion. There were no statistically significant differences between the two dose groups with regard to the number of injections, CMT, and change in visual acuity.

UR - http://www.scopus.com/inward/record.url?scp=77954723322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954723322&partnerID=8YFLogxK

U2 - 10.1097/IAE.0b013e3181cea68d

DO - 10.1097/IAE.0b013e3181cea68d

M3 - Article

VL - 30

SP - 1002

EP - 1011

JO - Retina

JF - Retina

SN - 0275-004X

IS - 7

ER -